Who are daclizumab, infliximab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab, Trastuzumab + Pertuzumab, Casirivimab and Imdevimab Drug Combination, Pertuzumab + trastuzumab, Pertuzumab and Trastuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daclizumab-infliximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

daclizumab, infliximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

daclizumab, infliximab (daclizumab, infliximab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody combination. Area: Immunology.

marketed Monoclonal antibody combination IL-2 receptor alpha (CD25) and TNF-alpha Immunology Small molecule Live · refreshed every 30 min

Target snapshot

daclizumab, infliximab (daclizumab, infliximab) — University of Iowa. This is a combination of two monoclonal antibodies: daclizumab blocks IL-2 receptor alpha on T cells to reduce immune activation, while infliximab blocks TNF-alpha to suppress inflammatory cytokine signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
daclizumab, infliximab TARGET	daclizumab, infliximab	University of Iowa	marketed	Monoclonal antibody combination	IL-2 receptor alpha (CD25) and TNF-alpha
Regeneron Casirivimab + Imdevimab	Regeneron Casirivimab + Imdevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein
Lilly Bamlanivimab + Etesevimab	Lilly Bamlanivimab + Etesevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
Trastuzumab + Pertuzumab	Trastuzumab + Pertuzumab	Massachusetts General Hospital	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
Pertuzumab + trastuzumab	Pertuzumab + trastuzumab	European Organisation for Research and Treatment of Cancer - EORTC	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Pertuzumab and Trastuzumab	Pertuzumab and Trastuzumab	QuantumLeap Healthcare Collaborative	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody combination class)

AstraZeneca · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
The First People's Hospital of Changzhou · 1 drug in this class
University of Iowa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). daclizumab, infliximab — Competitive Intelligence Brief. https://druglandscape.com/ci/daclizumab-infliximab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab